Abstract C082: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia
Year: 2025
Type: conference-abstract
Source: Molecular Cancer Therapeutics
Authors: Kerstin W. Sinkevicius, James P. Stice, Rui Xu, Cathy Zhang, Siyu Feng, Erin Riegler, Carlos Stahlhut, Kanchan Singh, Daniel J. Czyzyk, John-Paul Denson, Yue Yang, Sofia Donovan, Ming Chen, Cindy Feng, Kyle Sullivan, Nadege Gitego, Michela Ranieri, Magdalena Ploszaj, Katie Parker, Samar Ghorbanpoorvalukolaie, Marcin Dyba, Brian P. Smith, Lijuan Fu, Ken Lin, Felice C. Lightstone, Anna E. Maciag, Keshi Wang, Aaron Hata, Kwok-Kin Wong, Dwight V. Nissley, Eli Wallace, Dhirendra K. Simanshu, Frank McCormick, Pedro J. Beltran
Institutions: Frederick National Laboratory for Cancer Research, National Cancer Institute, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Harvard University, Massachusetts General Hospital, Lawrence Livermore National Laboratory, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4415444881
Cites:
Cited by:
Related to: